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Abstract
Background: Paraneoplastic neurological syndrome (PNS) is a heterogeneous group of disorders affecting any part
of the nervous system, in a patient affected by cancer. PNS is estimated to occur in 0.01 to 8 % of cancer patients,
with higher incidence in those with small cell lung cancer, gynecological tumours or hematological disease.
Paraneoplastic cerebellar degeneration (PCD) is the most common PNS, but it has never been reported in patients
with pancreatic well-differentiated neuroendocrine tumours.
Case presentation: A 61-year-old man presented with an unusual PNS and absence of circulating neural auto-
antibodies. Subsequently, contrast-enhanced computed tomography revealed a large pancreatic mass, together
with multiple liver metastases, histologically diagnosed as a well-differentiated neuroendocrine tumor. Initial
treatment with long-acting somatostatin analogue (octreotide LAR) and prednisone achieved a biochemical
response (reduction of chromogranin A level) and a radiological disease control, but patient experienced only a
brief improvement of neurological symptoms. Seven months after the onset of the symptoms, he died from
neurological impairment.
Conclusions: PNS can be associated with metastatic non-functioning well-differentiated pancreatic neuroendocrine
tumors. These tumors may be unresponsive to treatment with somatostatin analogues and an early neurological
treatment should be considered for the optimal management of these uncommon cases.
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Background
Paraneoplastic neurological syndrome (PNS) is a heteroge-
neous group of disorders affecting any part of the central,
peripheral or autonomic nervous system, associated with
the presence of a cancer. The etiology of these syndromes
has not been fully elucidated yet. Several authors investi-
gated the presence of tumour-associated antibodies against
neural antigens (anti-neural antibodies), defining PNS as an
immuno-mediated syndrome [1]. However, the absence of
anti-neural antibodies does not exclude a diagnosis of PNS,
as well as their presence is not sufficient to confirm this
diagnosis [2]. This syndrome occurs in 0.01 to 8 % of
patients with cancer, and its incidence is higher mainly
associated with small cell lung cancer, gynecological tumors
as well as hematological diseases [3]. In patients with well-
differentiated neuroendocrine tumours PNS has been only
occasionally reported.
Paraneoplastic cerebellar degeneration (PCD) is the
most common PNS and occurs as a result of autoimmune
damage to the cerebellum. It is characterized by subacute
cerebellar symptoms and exhibits varying clinical features:
In some cases only cerebellar involvement is noted,
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whereas other sites of the nervous system can be involved
in addition to the cerebellum. The syndrome develops
within days or a few weeks with dystasia, loss of ambula-
tion, dysarthria, saccadic gaze, pursuit, and nystagmus [3].
Diagnosis is driven by signs and symptoms, because
imaging techniques fail to show early abnormalities.
Radiological signs of cerebellar atrophy have been reported
only months after the clinical onset of the syndrome.
We report the case of a patient with symptoms of
sub-acute cerebellar degeneration, in which a pancre-
atic well-differentiated neuroendocrine tumor was
subsequently diagnosed.
Case presentation
A 61 year-old, Caucasian man, with controlled type II
diabetes, came to our attention in April 2011 because of
loss of balance that progressed over weeks. There was no
family history of neurological or autoimmune disorders. In
the preceding month, he started noticing body imbalance,
reduced ability to focus on daily activities, to elaborate
thoughts, and incoordination. Neurological examination
revealed signs associated with acute cerebellar degener-
ation, such as dysdiadochokinesia, mild dysarthria, dizzi-
ness, vertigo and clear ataxia. Baseline International
Cooperative Ataxia Rating Scale (ICARS score) [4] was 18.
Insulin, gastrin, glucagon, C-peptide, thyroid stimulating
hormone, thyroxine, folic acid, vitamin B-12 serum levels
and urinary 5-hydroxyindoleacetic acid (5HIAA) levels
were normal. Results of the lumbar puncture and lower
extremity electromyography were within physiological
limits. No brain masses or abnormalities were evident at
both magnetic resonance imaging (MRI) and computed
tomography (CT) scans. No neural auto-antibodies
(anti-Purkinje cells, anti-granule cells, anti-nucleolin,
anti-GABAergic synapses, DOT-BLOT IgG - Ravo)
were detected, neither in serum nor in cerebro-spinal
fluid (CSF). CSF analysis revealed an albumin level of
28,34 mg/dL and an IgG level of 4,50 mg/dL. The
cytology of CSF was negative for tumor cells. In May
2011, an abdominal CT scan revealed a large pancreatic
mass with multiple liver metastases (Fig. 1). Subsequently,
a percutaneous liver biopsy revealed pathological features
of well-differentiated neuroendocrine tumor (WDNET) of
the pancreas, with a 5 % proliferation index (Ki67). Serum
Chromogranin-A was elevated (524 U/l, upper normal
limit 18) and the 111In-octreotide scintigram resulted
positive. An early treatment with monthly intramuscular
octreotide LAR (long-acting releasing) at the dose of
30 mg and daily oral prednisone at the dose of 25 mg were
started. A complete disease restaging was performed in
September 2011. As expected, the size of the primary
lesion and of liver metastases did not change significantly,
whereas a good biochemical response was detected, with
Chromogranin-A serum level decreasing to 58 U/ml.
Clinically, the patient experienced an improvement in
neurological symptoms. However, three months later,
neurological symptoms rapidly worsened, requiring
hospitalization. Electroencephalogram (EEG) showed a
typical diffuse encephalopathy pattern, whereas the
brain MRI scan was negative. Despite an increase in the
dexamethazone daily dose up to 16 mg, during the
hospitalization the cerebellar syndrome further deterio-
rated, preventing patient’s self-care. In October 2011,
the ICARS score was 41 and Rankin scale 4 [5]. In
November 2011, seven months after the onset of the
symptoms, patient died from neurological impairment.
Fig. 1 Contrast computed tomography (CT) images of a patient with paraneoplastic cerebellar degeneration due to metastatic pancreatic
neuroendocrine tumour
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Discussion
According to diagnostic criteria, the clinical presentation
described above is a “classical” PNS. The patient developed
a severe pancerebellar syndrome in less than 12 weeks,
without evidence of cerebellar atrophy at the MRI, with a
progressive deteriorating clinical course, finally dying from
neurological impairment. Similarly to what reported in
literature [1], in our case the onset of PNS preceded the
diagnosis of a cancer. Thus, the presence of clinical findings
associated to PNS should focus the diagnostic work-up to
search for the presence of a neoplastic disease, even in the
absence of any positivity for neural antibodies. Several
studies [1, 3] reported cases of PNS in patients concomi-
tantly diagnosed with cancer. The tumors more commonly
involved are small cell lung cancer, gynecological cancers,
breast cancers, and Hodgkin’s lymphoma [3]. Only few
cases of PNS associated with pancreatic WDNET are
reported (Table 1) [6–8]. In these cases the treatment of
the underling cancer was followed by marked improvement
of neurological symptoms.
PCD is the most common PNS representing 24 % of all
the PNS, with well-defined criteria [3, 9]. In this case, the
onset and the time course of the neurological syndrome
fits the diagnosis of PCD, but grossly abnormal EEG and
the severity of global encephalopathy leading to death is
non typical for this syndrome.
To the best of our knowledge, the association between
a pancreatic WDNET and the detection of a PCD has
not previously been reported. Neurological impairment
and not tumor progression is often the cause of death in
these patients. Thus, treatment of PNS is symptomatic
and the complete surgical resection of the tumor is
highly encouraged [10].
Patients bearing well-differentiated, non-functioning
pancreatic neuroendocrine cancers usually present with a
slow-growing, less aggressive disease, with life expectancy
of more than 24 months [11]. Octreotide LAR is the
treatment of choice. In the absence of response, or in case
of progression, chemotherapy or everolimus may be
considered [12]. These treatments are associated with a
disease control (clinical and/or radiological) in more than
50 % of the patients [10]. The case here reported had an
atypical - and somehow unexpected - clinical course. After
three months of therapy, the patient presented with an
improvement of the neurological symptoms and a good
biochemical response, with a good correlation between
anti-tumor activity and control of clinical symptoms, as
usually observed in patients with this type of tumors.
Instead, the neurological impairment rapidly progressed
independently from the primary tumor response, and
precluded the administration of additional treatments. No
immunosuppressant agents or treatment with immuno-
globulins was administered. This was due to the quick and
fatal progression of the neurological symptoms. Further-
more, we recorded the absence of any immunoglobulin in
the CSF, so it is questionable whether such therapies
would have been beneficial in solving or at least stopping
the progressive deterioration of the overall condition.
Conclusion
This is the first report of an advanced well-differentiated
non-functioning neuroendocrine pancreatic tumor with
associated an acute paraneoplastic neurological syndrome
such as PCD. Neurological symptoms progressed inde-
pendently from the oncological course of the disease.
Thus an early neurological aggressive treatment should be
considered, even in the presence of a biochemical or
radiological response of the neuroendocrine tumor.
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Table 1 Case report of paraneoplastic neurological syndrome associated with well-differentiated pancreatic neuroendocrine tumor
Clinical syndrome Antibodies Reference
Lambert-Eaton myasthenic syndrome Not done Bertani et al. [6]
Paraneoplastic optic neuropathy CAR, CRMP-5, anti retinal negative, anti-optic nerve positive Slamovits et al. [7]
Paraneoplastic encephalomyelitis Anti Hu, Yo, Ri, Ma1-2, CV2, amphiphysin: negative, GAD positive Hernández-Echebarría et al. [8]
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